A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CONTINUED ENZALUTAMIDE TREATMENT BEYOND PROGRESSION IN PATIENTS WITH CHEMOTHERAPY-NAÏVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Latest Information Update: 20 Sep 2023
At a glance
- Drugs Enzalutamide (Primary) ; Abiraterone acetate; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms PLATO; PROSPER Study
- Sponsors Medivation; Pfizer
- 12 Oct 2022 Status changed from active, no longer recruiting to completed.
- 18 Sep 2022 This trial has been completed in Denmark, according to European Clinical Trials Database record (31 Aug 2022).
- 03 Jun 2022 This trial has been completed in Belgium, according to European Clinical Trials Database record.